Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most ...

Fresh off the release of clinical data showing its Tumor Treating Fields technology, or TTFields, helped improve survival rates for lung cancer patients compared to standard therapies alone, Novocure ...

As of Thursday, April 30, NovoCure Limited’s NVCR share price has surged by 19.53%, which has investors questioning if this is right time to sell.

Shares of Novocure (NASDAQ: NVCR) were trading 8.3% lower as of 10:55 a.m. ET on Thursday after the company announced organizational changes that were made, in its words, to "prepare for future growth ...

Shareholders will be ecstatic, with their stake up 33% over the past week following NovoCure Limited's (NASDAQ:NVCR) latest ...

Novocure sees its Relative Strength Rating enter the 80-plus level.

・The FDA approved Optune Pax for locally advanced pancreatic cancer. ・The Panova-3 trial showed Optune Pax, used alongside standard chemotherapy, improved median overall survival and delayed pain ...

Bull case: Novocure has several major catalysts on the way. Bear case: Investors could have a better entry point with Novocure. Many companies like to claim that they have revolutionary, game-changing ...

Bears are raising doubts about Novocure's clinical study design and peak market potential in non-small cell lung cancer (NSCLC). Bulls think the concerns are overblown and that Novocure could have a ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2023 on Thursday, May 4, 2023, before the U.S. financial markets ...

Novocure shareholders woke up to the pleasant news that Piper Sandler's Jason Bednar upped his recommendation on Novocure well before market open that day. Bednar has removed his previous neutral tag ...